As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors.
Gordon Mills, MD, PhD
Advertisement
Articles by Gordon Mills, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
3
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
4
TROPION-Breast01 and Comparative ADC Data
5